Evidence map›Paper›PMID 34635069›Full record

ArticleBMC infectious diseases2021

The resurgence of yellow fever outbreaks in Nigeria: a 2-year review 2017-2019.

Terna Nomhwange, Anne Eudes Jean Baptiste, Obi Ezebilo, Joseph Oteri, Lois Olajide, Kizito Emelife, Shehu Hassan, Erdoo R Nomhwange, Kennedy Adejoh, Faith Ireye and 4 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Mosquito gene targeted RNAi studies for vector control.Functional & integrative genomics · 2023
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Terna NomhwangeWorld Health Organization, Country Office, Abuja, Nigeria. nomhwanget@who.int.
Anne Eudes Jean BaptisteWorld Health Organization, Country Office, Abuja, Nigeria.
Obi EzebiloUnited Nations Children's Fund, Abuja, Nigeria.
Joseph OteriNational Primary Health Care Development Agency, Abuja, Nigeria.
Lois OlajideNigeria Centre for Disease Control, Abuja, Nigeria.
Kizito EmelifeNational Primary Health Care Development Agency, Abuja, Nigeria.
Shehu HassanNational Primary Health Care Development Agency, Abuja, Nigeria.
Erdoo R NomhwangeUniversity of Abuja Teaching Hospital, Abuja, Nigeria.
Kennedy AdejohWorld Health Organization-Nigeria, Abuja, Nigeria.
Faith IreyeWorld Health Organization-Nigeria, Abuja, Nigeria.
Eyo E NoraWorld Health Organization-Nigeria, Abuja, Nigeria.
Adamu NingiWorld Health Organization-Nigeria, Abuja, Nigeria.
Blaise BathondeliWorld Health Organization Regional Office for Africa, Brazzaville, Congo.
Oyewale TomoriIndependent Consultant and Professor of Virology, Abuja, Nigeria.

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundYellow fever outbreaks are documented to have a considerable impact not only on the individuals but on the health system with significant economic implications. Efforts to eliminate yellow fever outbreaks globally through the EYE strategy remains important following outbreaks in Africa, Nigeria included. The outbreaks reported in Nigeria, since 2017 and the response efforts provide an opportunity to document and guide interventions for improving future outbreaks in Nigeria and other countries in Africa.

methodsWe reviewed the available yellow fever surveillance and vaccination response data between September 2017 and September 2019 across the 36 states across Nigeria. We described the epidemiology of the difference outbreaks and the periods for all interventions. We also documented the emergency vaccination responses as well as preventive mass vaccinations implemented towards improving population immunity and limiting epidemic potentials in Nigeria.

resultsA total of 7894 suspected cases with 287 laboratory-confirmed cases were reported in Nigeria between September 2017 and September 2019 with a mean age of 19 years and a case fatality of 2.7% amongst all reported cases. Outbreaks were confirmed in 55 LGAs with most of the outbreaks across four major epicentres in Kwara/Kogi, Edo, Ebonyi and Bauchi states. In response to these outbreaks, eight reactive vaccination campaigns, supported through ICG applications, were implemented. The duration for responding to the outbreaks ranged from 15 to 132 days (average 68 days) and a total of 45,648,243 persons aged < 45 years vaccinated through reactive and preventive mass campaigns between September 2017 and September 2019.

conclusionsNigeria experienced intermediate outbreaks of yellow fever between September 2017 and 2019 with vaccination responses conducted to control these outbreaks. However, there are delays in the timeliness of responses and more efforts required in improving reporting, response times and preparedness to further prevent morbidity and mortality from the yellow fever disease outbreaks. These efforts, including improving routine yellow fever coverage, contribute towards improving population immunity and other activities related to achieving the goals of the EYE strategy.

Indexed as

Disease OutbreaksYellow FeverAdultHumansMass VaccinationNigeriaVaccinationYoung AdultArbovirusesEYE strategyVaccinationVPD outbreaksYellow fever

Identifiers

PMID34635069
PMCPMC8504075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.